Story perspectives

5th Circuit Restores In-Person Mifepristone Rule, Danco Seeks Stay

5/3/2026

47 8

Summary

Story summary

Fifth Circuit reinstated an in-person requirement for mifepristone Friday, overturning FDA policy that allowed remote dispensing.
Danco Laboratories, the Delaware manufacturer, filed an emergency Supreme Court application Saturday seeking a stay.
Plaintiffs cited a Federalist-only study claiming adverse effects 22 times higher than label reports.
Fourteen outlets reported the ruling, though fewer than half explained rationale, with The New York Times noting patient-care disruption and Fox News stressing Danco’s financial stake.

1 of 1

Story summary

Fifth Circuit reinstated an in-person requirement for mifepristone Friday, overturning FDA policy that allowed remote dispensing.
Danco Laboratories, the Delaware manufacturer, filed an emergency Supreme Court application Saturday seeking a stay.
Plaintiffs cited a Federalist-only study claiming adverse effects 22 times higher than label reports.
Fourteen outlets reported the ruling, though fewer than half explained rationale, with The New York Times noting patient-care disruption and Fox News stressing Danco’s financial stake.